A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension

REFERENCES

• Heijl A, Leske MC, Bengtsson B, et al, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
   PubMed Web of Science ®Google Scholar
• Costagliola C, dell’Omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure− part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009;10:2859–2870.
   PubMed Web of Science ®Google Scholar
• Costagliola C, dell’Omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother. 2009;10:2663–2677.
   PubMed Web of Science ®Google Scholar
• Stern FA, Bito LZ. Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes. Invest Ophthalmol Vis Sci. 1982;22:588–598.
   PubMed Web of Science ®Google Scholar
• Bito LZ, Draga A, Blanco J, Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci. 1983;24:312–319.
   PubMed Web of Science ®Google Scholar
• Bito LZ, Srinivasan BD, Baroody RA, Schubert H. Noninvasive observations on eyes of cats after long-term maintenance of reduced intraocular pressure by topical application of prostaglandin E2. Invest Ophthalmol Vis Sci. 1983;24:376–380.
   PubMed Web of Science ®Google Scholar
• Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103:147–166.
   PubMed Web of Science ®Google Scholar
• Bito LZ. Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds. Exp Eye Res. 1984;38:181–194.
   PubMed Web of Science ®Google Scholar
• Tsuji F, Hamada M, Shirasawa E. Tachykinins as enhancers of prostaglandin E2-induced intraocular inflammation. Ocul Immunol Inflamm. 1998;6:19–25.
   PubMed Web of Science ®Google Scholar
• Protzman CE, Woodward DF. Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype. Invest Ophthalmol Vis Sci. 1990;31:2463–2466.
   PubMed Web of Science ®Google Scholar
• Bhattacherjee P, Mukhopadhyay P, Tilley SL, et al. Blood-aqueous barrier in prostaglandin EP2 receptor knockout mice. Ocul Immunol Inflamm. 2002;10:187–196.
   PubMed Web of Science ®Google Scholar
• Biswas S, Bhattacherjee P, Paterson CA, et al. Ocular inflammatory responses in the EP2 and EP4 receptor knockout mice. Ocul Immunol Inflamm. 2006;14:157–163.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Geoghegan TE, Patil RV, et al. Detection of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle cells. Biochem Pharmacol. 1997;53:1249–1255.
   PubMed Web of Science ®Google Scholar
• Biswas S, Bhattacherjee P, Paterson CA. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4 in human and mouse ocular tissues—a comparative immunohistochemical study. Prostaglandins Leukot Essent Fatty Acids. 2004;71:277–288.
   PubMedGoogle Scholar
• Kamphuis W, Schneemann A, van Beek LM, et al. Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach. Invest Ophthalmol Vis Sci. 2001;42:3209–3215.
   PubMed Web of Science ®Google Scholar
• Kamphuis W, Schneemann A, Shichi H, et al. Immunolocalization of prostanoid EP receptor isotypes in human trabecular meshwork. Curr Eye Res. 2004;29:17–26.
   PubMed Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43:1475–1487.
   PubMed Web of Science ®Google Scholar
• Wang RF, Podos SM, Serle JB, et al. Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes. Arch Ophthalmol. 2000;118:74–77.
   PubMedGoogle Scholar
• Kottler UB, Junemann AG, Aigner T, Zenkel, et al. Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon’s capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp Eye Res. 2005;80:121–134.
   PubMed Web of Science ®Google Scholar
• Fleenor DL, Shepard AR, Helberg PE, et al. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47:226–234.
   PubMed Web of Science ®Google Scholar
• Robertson JV, Golesic E, Gauldie J, West-Mays JA. Ocular gene transfer of active TGF-beta induces changes in anterior segment morphology and elevated IOP in rats. Invest Ophthalmol Vis Sci. 2010;51:308–318.
   PubMedGoogle Scholar
• Choung J, Taylor L, Thomas K, et al. Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen α1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell Biochem. 1998;71:254–263.
   PubMedGoogle Scholar
• Tian M, Schiemann WP. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-β signaling during mammary tumorigenesis. FASEB J. 2010;24:1105–1116.
   PubMedGoogle Scholar
• Serle JB, Wang R-F, Mittag TW, et al. Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes. J Glaucoma. 2001;10:215–219.
   PubMed Web of Science ®Google Scholar